Lancet (London, England) 2023 Jul 18
Safe and effective systemic therapy for early-stage non-small-cell lung cancer.
Related Questions
New answer by Radiation Oncologist at Premiere Radiation Oncology (August 3, 2023)
Agree with the answers above and with some nuance. Completion of the phase III trials will be decisive in IO benefit in early-stage non-small cell lung cancer (ES-NSCLC). Howe...
Extrapolating from the ADRIATIC trial.
New comment by Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System ( February 18, 2025)
The randomized I-SABR results continue to intrigue me, even though they studied the efficacy of ICIs in NSCLC. The data has me leaning towards a few cycles of ICI "just to be ...